Literature DB >> 11509938

Increased hepatocyte growth factor in serum in acute graft-versus-host disease.

T Okamoto1, H Takatsuka, Y Fujimori, H Wada, T Iwasaki, E Kakishita.   

Abstract

Hepatocyte growth factor (HGF) was reported to be effective in preventing acute graft-versus-host disease (GVHD) in a murine model. We examined serum HGF concentrations in 38 patients receiving allogeneic bone marrow transplants, and investigated the relationship of serum HGF concentrations to severity of acute GVHD. More HGF was present in sera from patients with than without acute GVHD. Serum HGF correlated significantly with grade of acute GVHD. Furthermore, serum HGF correlated with serum concentrations of C-reactive protein, gamma-glutamyltranspeptidase (GTP), and aspartate aminotransferase (AST). Serum concentrations of HGF in transplanted patients without GVHD were consistently low, while those in patients with acute GVHD increased with exacerbation. We conclude that HGF was produced during induction of the GVH reaction, and probably increased as a physiological response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509938     DOI: 10.1038/sj.bmt.1703095

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  18 in total

1.  Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Authors:  Hartmut Koeppen; Wei Yu; Jiping Zha; Ajay Pandita; Elicia Penuel; Linda Rangell; Rajiv Raja; Sankar Mohan; Rajesh Patel; Rupal Desai; Ling Fu; An Do; Vaishali Parab; Xiaoling Xia; Tom Januario; Sharianne G Louie; Ellen Filvaroff; David S Shames; Ignacio Wistuba; Marina Lipkind; Jenny Huang; Mirella Lazarov; Vanitha Ramakrishnan; Lukas Amler; See-Chun Phan; Premal Patel; Amy Peterson; Robert L Yauch
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

Review 2.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 3.  Intestinal graft-versus-host disease: mechanisms and management.

Authors:  Hiroyuki Takatsuka; Tsuyoshi Iwasaki; Takahiro Okamoto; Eizo Kakishita
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

Review 5.  The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.

Authors:  Alaa M Ali; John F DiPersio; Mark A Schroeder
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-05       Impact factor: 5.742

Review 6.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

Review 7.  Recent advances in the treatment of graft-versus-host disease.

Authors:  Tsuyoshi Iwasaki
Journal:  Clin Med Res       Date:  2004-11

8.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Authors:  Mohamed L Sorror; Paul J Martin; Rainer F Storb; Smita Bhatia; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Christopher Davis; H Joachim Deeg; Stephanie J Lee; David G Maloney; Brenda M Sandmaier; Frederick R Appelbaum; Theodore A Gooley
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

Review 9.  Plasma biomarkers in graft-versus-host disease: a new era?

Authors:  Sophie Paczesny; John E Levine; Thomas M Braun; James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 10.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.